The proposed bill, General Assembly Committee Bill No. 6062, aims to prohibit direct-to-consumer advertisements for prescription drugs, specifically "legend drugs," within the state. The bill defines key terms such as "consumer," "pharmaceutical manufacturer," and "prescribing practitioner," all of which align with existing definitions in the general statutes. It stipulates that no person engaged in trade or commerce in the state may directly advertise these drugs to consumers. However, it allows registered pharmaceutical manufacturers and their representatives to promote or provide information about these drugs to prescribing practitioners.

Additionally, the bill grants the Commissioner of Consumer Protection the authority to adopt regulations to implement its provisions and establishes that any violations will be considered unfair or deceptive trade practices under existing law. The act is set to take effect on October 1, 2025, and introduces new legal language while removing any previous conflicting provisions. The intent of the bill is to enhance consumer protection by limiting exposure to direct pharmaceutical marketing.